Homology Medicines, Inc. FIXX
We take great care to ensure that the data presented and summarized in this overview for Homology Medicines, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in FIXX
Top Purchases
Top Sells
About FIXX
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
Insider Transactions at FIXX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 15
2024
|
Shelia M. Violette Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+20.08%
|
$42,000
$7.29 P/Share
|
|
Oct 11
2024
|
Shelia M. Violette Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,574
+20.38%
|
$13,722
$3.12 P/Share
|
|
Oct 08
2024
|
Shelia M. Violette Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,300
+50.0%
|
$39,900
$3.12 P/Share
|
|
Mar 25
2024
|
Arthur Tzianabos |
SELL
Open market or private sale
|
Direct |
265
-3.21%
|
$6,360
$24.2 P/Share
|
|
Mar 25
2024
|
Arthur Tzianabos |
BUY
Exercise of conversion of derivative security
|
Direct |
1,095
+11.72%
|
-
|
|
Mar 25
2024
|
Charles Michaud Jr |
SELL
Open market or private sale
|
Direct |
75
-7.49%
|
$1,800
$24.2 P/Share
|
|
Mar 25
2024
|
Paul Alloway |
SELL
Open market or private sale
|
Direct |
268
-9.36%
|
$6,432
$24.21 P/Share
|
|
Mar 25
2024
|
Charles Michaud Jr |
BUY
Exercise of conversion of derivative security
|
Direct |
6,448
+26.32%
|
-
|
|
Mar 25
2024
|
Paul Alloway |
BUY
Exercise of conversion of derivative security
|
Direct |
23,530
+31.33%
|
-
|
|
Jan 09
2024
|
Arthur Tzianabos |
SELL
Open market or private sale
|
Direct |
13,037
-9.19%
|
$0
$0.57 P/Share
|
|
Jan 03
2024
|
Paul Alloway |
SELL
Open market or private sale
|
Direct |
7,280
-20.61%
|
$0
$0.57 P/Share
|
|
Jan 03
2024
|
Charles Michaud Jr |
SELL
Open market or private sale
|
Direct |
1,708
-12.84%
|
$0
$0.57 P/Share
|
|
Jan 01
2024
|
Arthur Tzianabos |
BUY
Exercise of conversion of derivative security
|
Direct |
33,420
+11.16%
|
-
|
|
Jan 01
2024
|
Charles Michaud Jr |
BUY
Exercise of conversion of derivative security
|
Direct |
4,240
+10.31%
|
-
|
|
Jan 01
2024
|
Paul Alloway |
BUY
Exercise of conversion of derivative security
|
Direct |
18,610
+18.04%
|
-
|
|
Sep 06
2023
|
Albert Seymour |
SELL
Open market or private sale
|
Direct |
1,448
-0.95%
|
$1,448
$1.15 P/Share
|
|
Sep 06
2023
|
Albert Seymour |
BUY
Exercise of conversion of derivative security
|
Direct |
4,620
+2.94%
|
-
|
|
Aug 03
2023
|
Julie Jordan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,853
-9.17%
|
$1,853
$1.39 P/Share
|
|
Aug 03
2023
|
Julie Jordan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,579
+23.08%
|
-
|
|
Aug 02
2023
|
Julie Jordan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
99
-3.45%
|
$99
$1.31 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 111K shares |
|---|
| Open market or private sale | 22.6K shares |
|---|